Despite psilocybin's apparent effectiveness in depression, people with bipolar have been excluded from all modern trials.
Given the existing clinical and basic research, epidemiological studies, and published case histories, and importantly the lack of treatment options for depressive symptoms in bipolar disorder, we believe that a cautious approach to conducting trials in bipolar depression with psilocybin therapy.
"It is crucial that attention be given to a carefully regulated environment where researchers can screen participants, emphasize set and setting, and follow patients for an extended period."
Comments